Non-Alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases

Gut

Volumn 66, Issue 6, 2017, Pages 1138-1153

  Adams, Leon A ^a   Anstee, Quentin M ^b,c   Tilg, Herbert ^d   Targher, Giovanni ^e  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c FREEMAN HOSPITAL   (United Kingdom)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

Cardiovascular Disease; Diabetes Mellitus; Nonalcoholic Steatohepatitis

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN A1C; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; JUNCTIONAL ADHESION MOLECULE A; LOW DENSITY LIPOPROTEIN; MYELOID DIFFERENTIATION FACTOR 88; TRIMETHYLAMINE; TRIMETHYLAMINE OXIDE; TUMOR NECROSIS FACTOR; ADIPOCYTOKINE; CYTOKINE;

ARTICLE; AWARENESS; BODY MASS; BONE DENSITY; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; COLON CANCER; COLORECTAL ADENOMA; CYTOKINE RELEASE; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DYSLIPIDEMIA; EPIDEMIOLOGICAL DATA; EXTRAHEPATIC DISEASE; EXTRAHEPATIC NEOPLASM; GENETIC VARIABILITY; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; INCIDENCE; INSULIN RESISTANCE; INTESTINE FLORA; INTRAPERITONEAL FAT; KIDNEY FUNCTION; LIPID STORAGE; LIVER FIBROSIS; MALIGNANT NEOPLASM; METABOLIC RISK; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUTRITION; OSTEOPOROSIS; PATIENT CARE; PHYSICAL DISEASE; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SEX DIFFERENCE; ANIMAL; CARDIOVASCULAR DISEASES; COLORECTAL NEOPLASMS; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIET; METABOLISM; NUTRITIONAL STATUS; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC;

ADIPOKINES; ANIMALS; CARDIOVASCULAR DISEASES; COLORECTAL NEOPLASMS; CYTOKINES; DIABETES MELLITUS, TYPE 2; DIET; GASTROINTESTINAL MICROBIOME; HUMANS; INCIDENCE; NON-ALCOHOLIC FATTY LIVER DISEASE; NUTRITIONAL STATUS; OSTEOPOROSIS; PREVALENCE; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 85019439188     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2017-313884     Document Type: Article

References (199)

1. McPherson S, Hardy T, Henderson E, et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management. J Hepatol 2015;62:1148-55.
2. Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: A systematic review and meta-Analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015;13:643-54.e9.
3. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013;10:330-44.
4. Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015;61:1547-54.
5. Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-Term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015;149:389-97.e10.
6. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-31.
7. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-23.
8. Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010;53:372-84.
9. Kotronen A, Westerbacka J, Bergholm R, et al. Liver fat in the metabolic syndrome. J Clin Endocrinol Metab 2007;92:3490-7.
10. Li Y, Xu C, Yu C, et al. Association of serum uric acid level with non-Alcoholic fatty liver disease: A cross-sectional study. J Hepatol 2009;50:1029-34.
11. Sirota JC, McFann K, Targher G, et al. Elevated serum uric acid levels are associated with non-Alcoholic fatty liver disease independently of metabolic syndrome features in the United States: liver ultrasound data from the National Health and Nutrition Examination Survey. Metab Clin Exp 2013;62:392-9.
12. Petta S, Cammà C, Cabibi D, et al. Hyperuricemia is associated with histological liver damage in patients with non-Alcoholic fatty liver disease. Aliment Pharmacol Ther 2011;34:757-66.
13. Hui JM, Hodge A, Farrell GC, et al. Beyond insulin resistance in NASH: TNF-Alpha or adiponectin? Hepatology 2004;40:46-54.
14. Targher G, Bertolini L, Rodella S, et al. Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf ) 2006;64:679-83.
15. Bugianesi E, Pagotto U, Manini R, et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 2005;90:3498-504.
16. Targher G, Bertolini L, Scala L, et al. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-Alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2007;17:517-24.
17. Targher G, Chonchol M, Zoppini G, et al. Risk of chronic kidney disease in patients with non-Alcoholic fatty liver disease: is there a link? J Hepatol 2011;54:1020-9.
18. Targher G, Chonchol M, Miele L, et al. Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. Semin Thromb Hemost 2009;35:277-87.
19. Sookoian S, Castaño GO, Burgueño AL, et al. Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease. Atherosclerosis 2010;209:585-91.
20. Wieckowska A, Papouchado BG, Li Z, et al. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 2008;103:1372-9.
21. Sookoian S, Gianotti TF, Rosselli MS, et al. Liver transcriptional profile of atherosclerosis-related genes in human nonalcoholic fatty liver disease. Atherosclerosis 2011;218:378-85.
22. Weston CJ, Shepherd EL, Claridge LC, et al. Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis. J Clin Invest 2015;125:501-20.
23. Vanni E, Marengo A, Mezzabotta L, et al. Systemic complications of nonalcoholic fatty liver disease: when the liver is not an innocent bystander. Semin Liver Dis 2015;35:236-49.
24. Targher G, Bertolini L, Padovani R, et al. Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation. Diabetes Care 2004;27:2498-500.
25. Brea A, Mosquera D, Martín E, et al. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: A case-control study. Arterioscler Thromb Vasc Biol 2005;25:1045-50.
26. Volzke H, Robinson DM, Kleine V, et al. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. World J Gastroenterol 2005;11:1848-53.
27. Fracanzani AL, Burdick L, Raselli S, et al. Carotid artery intima-media thickness in nonalcoholic fatty liver disease. Am J Med 2008;121:72-8.
28. Kozakova M, Palombo C, Eng MP, et al. Fatty liver index, gamma-glutamyltransferase, and early carotid plaques. Hepatology 2012;55:1406-15.
29. Salvi P, Ruffini R, Agnoletti D, et al. Increased arterial stiffness in nonalcoholic fatty liver disease: The Cardio-GOOSE study. J Hypertens 2010;28:1699-707.
30. Lee YJ, Shim JY, Moon BS, et al. The relationship between arterial stiffness and nonalcoholic fatty liver disease. Dig Dis Sci 2012;57:196-203.
31. Villanova N, Moscatiello S, Ramilli S, et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005;42:473-80.
32. Pacifico L, Anania C, Martino F, et al. Functional and morphological vascular changes in pediatric nonalcoholic fatty liver disease. Hepatology 2010;52:1643-51.
33. Sookoian S, Pirola CJ. Non-Alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: A systematic review. J Hepatol 2008;49:600-7.
34. Oni ET, Agatston AS, Blaha MJ, et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis 2013;230:258-67.
35. Sung KC, Wild SH, Kwag HJ, et al. Fatty liver, insulin resistance, and features of metabolic syndrome: relationships with coronary artery calcium in 10, 153 people. Diabetes Care 2012;35:2359-64.
36. Goland S, Shimoni S, Zornitzki T, et al. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J Clin Gastroenterol 2006;40:949-55.
37. Fallo F, Dalla Pozza A, Sonino N, et al. Non-Alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension. Nutr Metab Cardiovasc Dis 2009;19:646-53.
38. Bonapace S, Perseghin G, Molon G, et al. Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. Diabetes Care 2012;35:389-95.
39. Hallsworth K, Hollingsworth KG, Thoma C, et al. Cardiac structure and function are altered in adults with non-Alcoholic fatty liver disease. J Hepatol 2013;58:757-62.
40. Perseghin G, Lattuada G, De Cobelli F, et al. Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology 2008;47:51-8.
41. Rijzewijk LJ, Jonker JT, van der Meer RW, et al. Effects of hepatic triglyceride content on myocardial metabolism in type 2 diabetes. J Am Coll Cardiol 2010;56:225-33.
42. Lautamäki R, Borra R, Iozzo P, et al. Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 2006;291:E282-90.
43. Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol 2012;10:646-50.
44. Lazo M, Hernaez R, Bonekamp S, et al. Non-Alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ 2011;343:d6891.
45. Targher G, Bertolini L, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007;30:1212-18.
46. Mirbagheri SA, Rashidi A, Abdi S, et al. Liver: An alarm for the heart? Liver Int 2007;27:891-4.
47. Assy N, Djibre A, Farah R, et al. Presence of coronary plaques in patients with nonalcoholic fatty liver disease. Radiology 2010;254:393-400.
48. Wong VW, Wong GL, Yeung JC, et al. Long-Term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study. Hepatology 2016;63:754-63.
49. Wu S, Wu F, Ding Y, et al. Association of non-Alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-Analysis. Sci Rep 2016;6:33386.
50. Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-Term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865-73.
51. Söderberg C, Stal P, Askling J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010;51:595-602.
52. Musso G, Gambino R, Cassader M, et al. Meta-Analysis: natural history of non-Alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011;43:617-49.
53. Sinn DH, Cho SJ, Gu S, et al. Persistent nonalcoholic fatty liver disease increases risk for carotid atherosclerosis. Gastroenterology 2016;151:481-8.e1.
54. Sinn DH, Kang D, Chang Y, et al. Non-Alcoholic fatty liver disease and progression of coronary artery calcium score: A retrospective cohort study. Gut 2017;66:323-9.
55. Pais R, Giral P, Khan JF, et al. Fatty liver is an independent predictor of early carotid atherosclerosis. J Hepatol 2016;65:95-102.
56. Ma J, Hwang SJ, Pedley A, et al. Bi-directional analysis between fatty liver and cardiovascular disease risk factors. J Hepatol 2017;66:390-7.
57. Kim D, Kim WR, Kim HJ, et al. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013;57:1357-65.
58. Haring R, Wallaschofski H, Nauck M, et al. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. Hepatology 2009;50:1403-11.
59. Hamaguchi M, Kojima T, Takeda N, et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 2007;13:1579-84.
60. Pisto P, Santaniemi M, Bloigu R, et al. Fatty liver predicts the risk for cardiovascular events in middle-Aged population: A population-based cohort study. BMJ Open 2014;4:e004973.
61. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 1999;116: 1413-19.
62. Dam-Larsen S, Franzmann M, Andersen IB, et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004;53:750-5.
63. Rafiq N, Bai C, Fang Y, et al. Long-Term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009;7:234-8.
64. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology 2005;129:113-21.
65. Jepsen P, Vilstrup H, Møller JK, et al. Prognosis of patients with liver cirrhosis and spontaneous bacterial peritonitis. Hepatogastroenterology 2003;50:2133-6.
66. Targher G, Bertolini L, Rodella S, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 2007;30:2119-21.
67. Zhou YJ, Li YY, Nie YQ, et al. Natural course of nonalcoholic fatty liver disease in southern China: A prospective cohort study. J Dig Dis 2012;13:153-60.
68. Targher G, Byrne CD, Lonardo A, et al. Non-Alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-Analysis. J Hepatol 2016;65:589-600.
69. Anstee QM, Day CP. The genetics of nonalcoholic fatty liver disease: spotlight on PNPLA3 and TM6SF2. Semin Liver Dis 2015;35:270-90.
70. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40:1461-5.
71. Valenti L, Al-Serri A, Daly AK, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010;51:1209-17.
72. Liu YL, Patman GL, Leathart JB, et al. Carriage of the PNPLA3 rs738409 CG polymorphism confers an increased risk of non-Alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol 2014;61:75-81.
73. Lonardo A, Ballestri S, Targher G. "Not all forms of NAFLD were created equal". Do metabolic syndrome-related NAFLD and PNPLA3-related NAFLD exert a variable impact on the risk of early carotid atherosclerosis? Atherosclerosis 2017;257:253-5.
74. Kozlitina J, Smagris E, Stender S, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2014;46:352-6.
75. Liu YL, Reeves HL, Burt AD, et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-Alcoholic fatty liver disease. Nat Commun 2014;5:4309.
76. Dongiovanni P, Petta S, Maglio C, et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology 2015;61:506-14.
77. Holmen OL, Zhang H, Fan Y, et al. Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk. Nat Genet 2014;46:345-51.
78. Kahali B, Liu YL, Daly AK, et al. TM6SF2: catch-22 in the fight against nonalcoholic fatty liver disease and cardiovascular disease? Gastroenterology 2015;148:679-84.
79. Zeybel M, Hardy T, Wong YK, et al. Multigenerational epigenetic adaptation of the hepatic wound-healing response. Nat Med 2012;18:1369-77.
80. Zeybel M, Hardy T, Robinson SM, et al. Differential DNA methylation of genes involved in fibrosis progression in non-Alcoholic fatty liver disease and alcoholic liver disease. Clin Epigenetics 2015;7:25.
81. Hardy T, Zeybel M, Day CP, et al. Plasma DNA methylation: A potential biomarker for stratification of liver fibrosis in non-Alcoholic fatty liver disease. Gut 2016. doi: 10.1136/gutjnl-2016-311526. [Epub ahead of print 21 Mar 2016].
82. Ma Y, Ordovas JM. The integration of epigenetics and genetics in nutrition research for CVD risk factors. Proc Nutr Soc 2016:1-14.
83. Käräjämäki AJ, Pätsi OP, Savolainen M, et al. Non-Alcoholic fatty liver disease as a predictor of atrial fibrillation in middle-Aged population (OPERA study). PLoS One 2015;10:e0142937.
84. Targher G, Valbusa F, Bonapace S, et al. Non-Alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PLoS One 2013;8:e57183.
85. Mantovani A, Pernigo M, Bergamini C, et al. Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver disease. Metab Clin Exp 2015;64:879-87.
86. Hung CS, Tseng PH, Tu CH, et al. Nonalcoholic fatty liver disease is associated with QT prolongation in the general population. J Am Heart Assoc 2015;4: e001820.
87. Mantovani A, Rigamonti A, Bonapace S, et al. Nonalcoholic fatty liver disease is associated with ventricular arrhythmias in patients with type 2 diabetes referred for clinically indicated 24-hour Holter monitoring. Diabetes Care 2016;39:1416-23.
88. Treeprasertsuk S, Leverage S, Adams LA, et al. The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int 2012;32:945-50.
89. Targher G, Bertolini L, Rodella S, et al. Non-Alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-Treated retinopathy in type 2 diabetic patients. Diabetologia 2008;51:444-50.
90. Targher G, Bertolini L, Chonchol M, et al. Non-Alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients. Diabetologia 2010;53:1341-8.
91. Li G, Shi W, Hug H, et al. Nonalcoholic fatty liver disease associated with impairment of kidney function in nondiabetes population. Biochem Med (Zagreb) 2012;22:92-9.
92. Sirota JC, McFann K, Targher G, et al. Association between nonalcoholic liver disease and chronic kidney disease: An ultrasound analysis from NHANES 1988-1994. Am J Nephrol 2012;36:466-71.
93. Ahn AL, Choi JK, Kim MN, et al. Non-Alcoholic fatty liver disease and chronic kidney disease in Koreans aged 50 years or older. Korean J Fam Med 2013;34:199-205.
94. Mikolasevic I, Racki S, Bubic I, et al. Chronic kidney disease and nonalcoholic Fatty liver disease proven by transient elastography. Kidney Blood Press Res 2013;37:305-10.
95. Jia G, Di F, Wang Q, et al. Non-Alcoholic fatty liver disease is a risk factor for the development of diabetic nephropathy in patients with type 2 diabetes mellitus. PLoS One 2015;10:e0142808.
96. Pan LL, Zhang HJ, Huang ZF, et al. Intrahepatic triglyceride content is independently associated with chronic kidney disease in obese adults: A cross-sectional study. Metab Clin Exp 2015;64:1077-85.
97. Xu HW, Hsu YC, Chang CH, et al. High FIB-4 index as an independent risk factor of prevalent chronic kidney disease in patients with nonalcoholic fatty liver disease. Hepatol Int 2016;10:340-6.
98. Pacifico L, Bonci E, Andreoli GM, et al. The impact of nonalcoholic fatty liver disease on renal function in children with overweight/obesity. Int J Mol Sci 2016;17.
99. Targher G, Bertolini L, Rodella S, et al. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol 2010;5:2166-71.
100. Yilmaz Y, Alahdab YO, Yonal O, et al. Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: Association with liver fibrosis. Metab Clin Exp 2010;59:1327-30.
101. Yasui K, Sumida Y, Mori Y, et al. Nonalcoholic steatohepatitis and increased risk of chronic kidney disease. Metab Clin Exp 2011;60:735-9.
102. Park CW, Tsai NT, Wong LL. Implications of worse renal dysfunction and medical comorbidities in patients with NASH undergoing liver transplant evaluation: impact on MELD and more. Clin Transplant 2011;25:E606-11.
103. Machado MV, Gonçalves S, Carepa F, et al. Impaired renal function in morbid obese patients with nonalcoholic fatty liver disease. Liver Int 2012;32:241-8.
104. Lin L, Lu J, Huang X, et al. Nonalcoholic fatty liver disease is associated with low-grade albuminuria in Chinese adults (change not displayed). QJM 2016;109:737-43.
105. Musso G, Cassader M, Cohney S, et al. Fatty liver and chronic kidney disease: novel mechanistic insights and therapeutic opportunities. Diabetes Care 2016;39:1830-45.
106. Targher G, Chonchol MB, Byrne CD. CKD and nonalcoholic fatty liver disease. Am J Kidney Dis 2014;64:638-52.
107. Chang Y, Ryu S, Sung E, et al. Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men. Metab Clin Exp 2008;57:569-76.
108. Targher G, Chonchol M, Bertolini L, et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol 2008;19:1564-70.
109. Targher G, Mantovani A, Pichiri I, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes. Diabetes Care 2014;37:1729-36.
110. Musso G, Gambino R, Tabibian JH, et al. Association of non-Alcoholic fatty liver disease with chronic kidney disease: A systematic review and meta-Analysis. PLoS Med 2014;11:e1001680.
111. Vilar-Gomez E, Calzadilla-Bertot L, Friedman SL, et al. Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non-Alcoholic steatohepatitis. Aliment Pharmacol Ther 2017;45:332-44.
112. Wong VW, Chu WC, Wong GL, et al. Prevalence of non-Alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: A population study using protonmagnetic resonance spectroscopy and transient elastography. Gut 2012;61:409-15.
113. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-95.
114. Kwok R, Choi KC, Wong GL, et al. Screening diabetic patients for non-Alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: A prospective cohort study. Gut 2016;65:1359-68.
115. Fabbrini E, Yoshino J, Yoshino M, et al. Metabolically normal obese people are protected from adverse effects following weight gain. J Clin Invest 2015;125:787-95.
116. Perry IJ, Wannamethee SG, Shaper AG. Prospective study of serum gamma-glutamyltransferase and risk of NIDDM. Diabetes Care 1998;21:732-7.
117. Ballestri S, Zona S, Targher G, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-Analysis. J Gastroenterol Hepatol 2016;31:936-44.
118. Balkau B, Lange C, Vol S, et al. Group Study DESIR. Nine-year incident diabetes is predicted by fatty liver indices: The French D.E.S.I.R. study. BMC Gastroenterol 2010;10:56.
119. Chang Y, Jung HS, Yun KE, et al. Cohort study of non-Alcoholic fatty liver disease, NAFLD fibrosis score, and the risk of incident diabetes in a Korean population. Am J Gastroenterol 2013;108:1861-8.
120. Chen GY, Cao HX, Li F, et al. New risk-scoring system including non-Alcoholic fatty liver disease for predicting incident type 2 diabetes in East China: Shanghai Baosteel Cohort. J Diabetes Investig 2016;7:206-11.
121. Fukuda T, Hamaguchi M, Kojima T, et al. The impact of non-Alcoholic fatty liver disease on incident type 2 diabetes mellitus in non-overweight individuals. Liver Int 2016;36:275-83.
122. Kim CH, Park JY, Lee KU, et al. Fatty liver is an independent risk factor for the development of Type 2 diabetes in Korean adults. Diabet Med 2008;25:476-81.
123. Ming J, Xu S, Gao B, et al. Non-Alcoholic fatty liver disease predicts type 2 diabetes mellitus, but not prediabetes, in Xian, China: A five-year cohort study. Liver Int 2015;35:2401-7.
124. Okamoto M, Takeda Y, Yoda Y, et al. The association of fatty liver and diabetes risk. J Epidemiol 2003;13:15-21.
125. Park SK, Seo MH, Shin HC, et al. Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study. Hepatology 2013;57:1378-83.
126. Shah RV, Allison MA, Lima JA, et al. Liver fat, statin use, and incident diabetes: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 2015;242:211-17.
127. Sung KC, Kim SH. Interrelationship between fatty liver and insulin resistance in the development of type 2 diabetes. J Clin Endocrinol Metab 2011;96:1093-7.
128. Yamada T, Fukatsu M, Suzuki S, et al. Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup. J Gastroenterol Hepatol 2010;25:352-6.
129. Yamazaki H, Tsuboya T, Tsuji K, et al. Independent association between improvement of nonalcoholic fatty liver disease and reduced incidence of type 2 diabetes. Diabetes Care 2015;38:1673-9.
130. Sung KC, Wild SH, Byrne CD. Resolution of fatty liver and risk of incident diabetes. J Clin Endocrinol Metab 2013;98:3637-43.
131. Fukuda T, Hamaguchi M, Kojima T, et al. Transient remission of nonalcoholic fatty liver disease decreases the risk of incident type 2 diabetes mellitus in Japanese men. Eur J Gastroenterol Hepatol 2016;28:1443-9.
132. Sung KC, Jeong WS, Wild SH, et al. Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes. Diabetes Care 2012;35:717-22.
133. Bae JC, Rhee EJ, Lee WY, et al. Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: A 4-year retrospective longitudinal study. Diabetes Care 2011;34:727-9.
134. Käräjämäki AJ, Bloigu R, Kauma H, et al. Non-Alcoholic fatty liver disease with and without metabolic syndrome: different long-Term outcomes. Metab Clin Exp 2017;66:55-63.
135. Choi JH, Rhee EJ, Bae JC, et al. Increased risk of type 2 diabetes in subjects with both elevated liver enzymes and ultrasonographically diagnosed nonalcoholic fatty liver disease: A 4-year longitudinal study. Arch Med Res 2013;44:115-20.
136. Lin TY, Chen YJ, Chen WL, et al. The relationship between nonalcoholic fatty liver disease and retinopathy in NHANES III. PLoS One 2016;11:e0165970.
137. Amaro A, Fabbrini E, Kars M, et al. Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia. Gastroenterology 2010;139:149-53.
138. Palmer CN, Maglio C, Pirazzi C, et al. Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant. PLoS ONE 2012;7:e39362.
139. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-Alcoholic fatty liver disease. J Hepatol 2016;64:1388-402.
140. Adams LA, Harmsen S, St Sauver JL, et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: A community-based cohort study. Am J Gastroenterol 2010;105:1567-73.
141. Huang KW, Leu HB, Wang YJ, et al. Patients with nonalcoholic fatty liver disease have higher risk of colorectal adenoma after negative baseline colonoscopy. Colorectal Dis 2013;15:830-5.
142. Ding W, Fan J, Qin J. Association between nonalcoholic fatty liver disease and colorectal adenoma: A systematic review and meta-Analysis. Int J Clin Exp Med 2015;8:322-33.
143. Shen H, Lipka S, Kumar A, et al. Association between nonalcoholic fatty liver disease and colorectal adenoma: A systemic review and meta-Analysis. J Gastrointest Oncol 2014;5:440-6.
144. Wong VW, Wong GL, Tsang SW, et al. High prevalence of colorectal neoplasm in patients with non-Alcoholic steatohepatitis. Gut 2011;60:829-36.
145. Touzin NT, Bush KN, Williams CD, et al. Prevalence of colonic adenomas in patients with nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2011;4:169-76.
146. Ahn JS, Sinn DH, Min YW, et al. Non-Alcoholic fatty liver diseases and risk of colorectal neoplasia. Aliment Pharmacol Ther 2017;45:345-53.
147. Lee YI, Lim YS, Park HS. Colorectal neoplasms in relation to non-Alcoholic fatty liver disease in Korean women: A retrospective cohort study. J Gastroenterol Hepatol 2012;27:91-5.
148. Lin XF, Shi KQ, You J, et al. Increased risk of colorectal malignant neoplasm in patients with nonalcoholic fatty liver disease: A large study. Mol Biol Rep 2014;41:2989-97.
149. Sanna C, Rosso C, Marietti M, et al. Non-Alcoholic fatty liver disease and extra-hepatic cancers. Int J Mol Sci 2016;17:E717.
150. Targher G, Lonardo A, Rossini M. Nonalcoholic fatty liver disease and decreased bone mineral density: is there a link? J Endocrinol Invest 2015;38:817-25.
151. Pardee PE, Dunn W, Schwimmer JB. Non-Alcoholic fatty liver disease is associated with low bone mineral density in obese children. Aliment Pharmacol Ther 2012;35:248-54.
152. Upala S, Jaruvongvanich V, Wijarnpreecha K, et al. Nonalcoholic fatty liver disease and osteoporosis: A systematic review and meta-Analysis. J Bone Miner Metab 2016.
153. Xia MF, Lin HD, Yan HM, et al. The association of liver fat content and serum alanine aminotransferase with bone mineral density in middle-Aged and elderly Chinese men and postmenopausal women. J Transl Med 2016;14:11.
154. Lee SH, Yun JM, Kim SH, et al. Association between bone mineral density and nonalcoholic fatty liver disease in Korean adults. J Endocrinol Invest 2016;39:1329-36.
155. Yang HJ, Shim SG, Ma BO, et al. Association of nonalcoholic fatty liver disease with bone mineral density and serum osteocalcin levels in Korean men. Eur J Gastroenterol Hepatol 2016;28:338-44.
156. Li M, Xu Y, Xu M, et al. Association between nonalcoholic fatty liver disease (NAFLD) and osteoporotic fracture in middle-Aged and elderly Chinese. J Clin Endocrinol Metab 2012;97:2033-8.
157. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol 2011;29:415-45.
158. Pihlajämaki J, Kuulasmaa T, Kaminska D, et al. Serum interleukin 1 receptor antagonist as an independent marker of non-Alcoholic steatohepatitis in humans. J Hepatol 2012;56:663-70.
159. Tilg H, Moschen AR, Szabo G. Interleukin-1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology 2016;64:955-65.
160. Johnson AM, Olefsky JM. The origins and drivers of insulin resistance. Cell 2013;152:673-84.
161. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology 2010;52:1836-46.
162. Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-Alpha, in vivo. J Clin Endocrinol Metab 1997;82:4196-200.
163. Mottillo EP, Desjardins EM, Crane JD, et al. Lack of adipocyte AMPK exacerbates insulin resistance and hepatic steatosis through brown and beige adipose tissue function. Cell Metab 2016;24:118-29.
164. Softic S, Boucher J, Solheim MH, et al. Lipodystrophy due to adipose tissue-specific insulin receptor knockout results in progressive NAFLD. Diabetes 2016;65:2187-200.
165. Wieser V, Adolph TE, Grander C, et al. Adipose type I interferon signalling protects against metabolic dysfunction. Gut 2016. doi: 10.1136/gutjnl-2016-313155. [Epub ahead of print 23 Dec 2016].
166. Kau AL, Ahern PP, Griffin NW, et al. Human nutrition, the gut microbiome and the immune system. Nature 2011;474:327-36.
167. Tilg H, Moschen AR. Food, immunity, and the microbiome. Gastroenterology 2015;148:1107-19.
168. Kleinewietfeld M, Manzel A, Titze J, et al. Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. Nature 2013;496:518-22.
169. Calder PC. Fatty acids and inflammation: The cutting edge between food and pharma. Eur J Pharmacol 2011;668(Suppl 1):S50-8.
170. Bischoff SC, Barbara G, Buurman W, et al. Intestinal permeability-A new target for disease prevention and therapy. BMC Gastroenterol 2014;14: 189.
171. Rahman K, Desai C, Iyer SS, et al. Loss of junctional adhesion molecule a promotes severe steatohepatitis in mice on a diet high in saturated fat, fructose, and cholesterol. Gastroenterology 2016;151:733-46.e12.
172. Pendyala S, Walker JM, Holt PR. A high-fat diet is associated with endotoxemia that originates from the gut. Gastroenterology 2012;142:1100-1.e2.
173. Devkota S, Wang Y, Musch MW, et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/-mice. Nature 2012;487:104-8.
174. Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011;472:57-63.
175. Jegatheesan P, Beutheu S, Freese K, et al. Preventive effects of citrulline on Western diet-induced non-Alcoholic fatty liver disease in rats. Br J Nutr 2016;116:191-203.
176. Tilg H, Cani PD, Mayer EA. Gut microbiome and liver diseases. Gut 2016;65:2035-44.
177. Del Chierico F, Nobili V, Vernocchi P, et al. Gut microbiota profiling of pediatric NAFLD and obese patients unveiled by an integrated meta-omics based approach. Hepatology 2017;65:451-64.
178. Boursier J, Mueller O, Barret M, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 2016;63:764-75.
179. Yoshimoto S, Loo TM, Atarashi K, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013;499:97-101.
180. Feng Q, Liang S, Jia H, et al. Gut microbiome development along the colorectal adenoma-carcinoma sequence. Nat Commun 2015;6:6528.
181. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000;343:1467-76.
182. Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005;11:183-90.
183. Arkan MC, Hevener AL, Greten FR, et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 2005;11:191-8.
184. Kiechl S, Wittmann J, Giaccari A, et al. Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat Med 2013;19:358-63.
185. Duparc T, Plovier H, Marrachelli VG, et al. Hepatocyte MyD88 affects bile acids, gut microbiota and metabolome contributing to regulate glucose and lipid metabolism. Gut 2016. doi: gutjnl-2015-310904. [Epub ahead of print 5 May 2016].
186. Zoller H, Tilg H. Nonalcoholic fatty liver disease and hepatocellular carcinoma. Metab Clin Exp 2016;65:1151-60.
187. Park EJ, Lee JH, Yu GY, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010;140:197-208.
188. Kaser S, Moschen A, Cayon A, et al. Adiponectin and its receptors in non-Alcoholic steatohepatitis. Gut 2005;54:117-21.
189. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006;6:772-83.
190. Wei EK, Giovannucci E, Fuchs CS, et al. Low plasma adiponectin levels and risk of colorectal cancer in men: A prospective study. J Natl Cancer Inst 2005;97:1688-94.
191. Yamaji T, Iwasaki M, Sasazuki S, et al. Interaction between adiponectin and leptin influences the risk of colorectal adenoma. Cancer Res 2010;70:5430-7.
192. Inamura K, Song M, Jung S, et al. Prediagnosis plasma adiponectin in relation to colorectal cancer risk according to KRAS mutation status. J Natl Cancer Inst 2016;108.
193. Fracanzani AL, Tiraboschi S, Pisano G, et al. Progression of carotid vascular damage and cardiovascular events in non-Alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up. Atherosclerosis 2016;246:208-13.
194. Mantovani A, Mingolla L, Rigolon R, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular disease in adult patients with type 1 diabetes. Int J Cardiol 2016;225:387-91.
195. Zeb I, Li D, Budoff MJ, et al. Nonalcoholic fatty liver disease and incident cardiac events: The multi-ethnic study of atherosclerosis. J Am Coll Cardiol 2016;67:1965-6.
196. Hwang ST, Cho YK, Park JH, et al. Relationship of non-Alcoholic fatty liver disease to colorectal adenomatous polyps. J Gastroenterol Hepatol 2010;25:562-7.
197. Stadlmayr A, Aigner E, Steger B, et al. Nonalcoholic fatty liver disease: An independent risk factor for colorectal neoplasia. J Intern Med 2011;270:41-9.
198. Bhatt BD, Lukose T, Siegel AB, et al. Increased risk of colorectal polyps in patients with non-Alcoholic fatty liver disease undergoing liver transplant evaluation. J Gastrointest Oncol 2015;6:459-68.
199. Basyigit S, Uzman M, Kefeli A, et al. Absence of non-Alcoholic fatty liver disease in the presence of insulin resistance is a strong predictor for colorectal carcinoma. Int J Clin Exp Med 2015;8:18601-10.